Mississauga, ON, Canada - June 4, 2015, Mississauga, ON, Canada - Cipher Pharmaceuticals has appointed Louise Blythe as vice president, regulatory affairs, and Brian Rosenberger as vice president, alliance and strategic portfolio management.
Article continues below
Ms. Blythe brings to Cipher 16 years of experience in regulatory affairs in the pharmaceutical industry. Most recently, she served as director of regulatory affairs and quality assurance at Forest Laboratories Canada Inc., where she was instrumental in establishing Forest Laboratories' Canadian subsidiary and building the regulatory and quality assurance department.
Prior thereto, Ms. Blythe held various positions of increasing responsibility within regulatory affairs at AstraZeneca Canada Inc., including head of strategic product development and life cycle management.
Mr. Rosenberger brings to Cipher over two decades experience in the biopharmaceutical industry, specifically in specialty markets, having served in leadership roles across a variety of areas, including marketing, sales, market research, business development, portfolio management and alliance management.
Mr. Rosenberger joins Cipher from Auxilium Pharmaceuticals Inc., where he was initially responsible for marketing the company's flagship brand, Testim, a testosterone gel. Most recently, he held a dual role, which included running the alliance management function across numerous global partners, as well as managing the company's business development activities.
In addition, the company announced the promotions of Joan Chypyha to president and general manager, Canada, and Joe Pecora to president and general manager, United States.
Ms. Chypyha joined Cipher in March, 2013, as vice president, marketing and sales, and has since led the company's marketing and sales force across Canada. She has overseen the growth in Cipher's lead Canadian dermatology product, Epuris.
With more than 25 years experience, Ms. Chypyha has served in numerous leadership roles, including chief development officer of Rhei Pharmaceuticals Ltd.; vice president, corporate development, at Barrier Therapeutics Inc.; general manager of Barrier Therapeutics Canada Inc; and founder of Alto Pharmaceuticals Ltd. ■